Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation

University of Kansas Medical Center254 enrolled

Overview

The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate weight gain during pregnancy impacts this result.

Study Type

OBSERVATIONAL

Enrollment

254

Conditions

Pregnancy; Nutritional Diseases

Eligibility

Sex: FEMALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Participants for this study are invited from the parent study, ADORE. Eligibility listed reflects criteria for the ADORE study. Inclusion Criteria: * Agree to consume study capsules and a typical prenatal supplement of 200 mg DHA * Available by telephone Exclusion Criteria: * Expecting multiple infants * Gestational age at baseline \<12 weeks or \>20 weeks * Unable or unwilling to agree to consume capsules until delivery * Unwilling to discontinue use of another prenatal supplement with DHA that contains ≥ 200 mg DHA * Women with allergy to any component of DHA product (including algae), soybean oil or corn oil

Locations (1)

The University of Kansas Medical Center

Kansas City, Kansas, United States

Outcomes

Primary Outcomes

Infant Fat Mass (FM)

Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG

Time frame: 24 months

Secondary Outcomes

Central Fat Mass

Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.